Global Pharmacogenomics Technology (Theranostics and CDx) Market Research Report 2024(Status and Outlook)
Report Overview:
The Global Pharmacogenomics Technology (Theranostics and CDx) Market Size was estimated at USD 4221.19 million in 2023 and is projected to reach USD 9612.04 million by 2029, exhibiting a CAGR of 14.70% during the forecast period.
This report provides a deep insight into the global Pharmacogenomics Technology (Theranostics and CDx) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pharmacogenomics Technology (Theranostics and CDx) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pharmacogenomics Technology (Theranostics and CDx) market in any manner.
Global Pharmacogenomics Technology (Theranostics and CDx) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics
Market Segmentation (by Type)
Instrument
Reagents and Consumables
Others
Market Segmentation (by Application)
Tumor
Diabetes
Mental Diseases
Cardiovascular Diseases
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pharmacogenomics Technology (Theranostics and CDx) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
The Global Pharmacogenomics Technology (Theranostics and CDx) Market Size was estimated at USD 4221.19 million in 2023 and is projected to reach USD 9612.04 million by 2029, exhibiting a CAGR of 14.70% during the forecast period.
This report provides a deep insight into the global Pharmacogenomics Technology (Theranostics and CDx) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pharmacogenomics Technology (Theranostics and CDx) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pharmacogenomics Technology (Theranostics and CDx) market in any manner.
Global Pharmacogenomics Technology (Theranostics and CDx) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics
Market Segmentation (by Type)
Instrument
Reagents and Consumables
Others
Market Segmentation (by Application)
Tumor
Diabetes
Mental Diseases
Cardiovascular Diseases
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Pharmacogenomics Technology (Theranostics and CDx) Market
- Overview of the regional outlook of the Pharmacogenomics Technology (Theranostics and CDx) Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pharmacogenomics Technology (Theranostics and CDx) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Pharmacogenomics Technology (Theranostics and CDx)
1.2 Key Market Segments
1.2.1 Pharmacogenomics Technology (Theranostics and CDx) Segment by Type
1.2.2 Pharmacogenomics Technology (Theranostics and CDx) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET COMPETITIVE LANDSCAPE
3.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Manufacturers (2019-2024)
3.2 Global Pharmacogenomics Technology (Theranostics and CDx) Revenue Market Share by Manufacturers (2019-2024)
3.3 Pharmacogenomics Technology (Theranostics and CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Pharmacogenomics Technology (Theranostics and CDx) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Pharmacogenomics Technology (Theranostics and CDx) Sales Sites, Area Served, Product Type
3.6 Pharmacogenomics Technology (Theranostics and CDx) Market Competitive Situation and Trends
3.6.1 Pharmacogenomics Technology (Theranostics and CDx) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Pharmacogenomics Technology (Theranostics and CDx) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) INDUSTRY CHAIN ANALYSIS
4.1 Pharmacogenomics Technology (Theranostics and CDx) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Type (2019-2024)
6.3 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Market Share by Type (2019-2024)
6.4 Global Pharmacogenomics Technology (Theranostics and CDx) Price by Type (2019-2024)
7 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Sales by Application (2019-2024)
7.3 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) by Application (2019-2024)
7.4 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Growth Rate by Application (2019-2024)
8 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET SEGMENTATION BY REGION
8.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.1.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.1.2 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region
8.2 North America
8.2.1 North America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Pharmacogenomics Technology (Theranostics and CDx) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Illumina
9.1.1 Illumina Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.1.2 Illumina Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.1.3 Illumina Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.1.4 Illumina Business Overview
9.1.5 Illumina Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
9.1.6 Illumina Recent Developments
9.2 Roche
9.2.1 Roche Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.2.2 Roche Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.2.3 Roche Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
9.2.6 Roche Recent Developments
9.3 Agilent
9.3.1 Agilent Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.3.2 Agilent Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.3.3 Agilent Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.3.4 Agilent Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
9.3.5 Agilent Business Overview
9.3.6 Agilent Recent Developments
9.4 Abbott
9.4.1 Abbott Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.4.2 Abbott Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.4.3 Abbott Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.4.4 Abbott Business Overview
9.4.5 Abbott Recent Developments
9.5 Thermofisher
9.5.1 Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.5.2 Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.5.3 Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.5.4 Thermofisher Business Overview
9.5.5 Thermofisher Recent Developments
9.6 Qiagen
9.6.1 Qiagen Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.6.2 Qiagen Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.6.3 Qiagen Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.6.4 Qiagen Business Overview
9.6.5 Qiagen Recent Developments
9.7 Guardant Health
9.7.1 Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.7.2 Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.7.3 Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.7.4 Guardant Health Business Overview
9.7.5 Guardant Health Recent Developments
9.8 MGI Tech Co., Ltd.
9.8.1 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.8.2 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.8.4 MGI Tech Co., Ltd. Business Overview
9.8.5 MGI Tech Co., Ltd. Recent Developments
9.9 Amoydx Biology
9.9.1 Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.9.2 Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.9.4 Amoydx Biology Business Overview
9.9.5 Amoydx Biology Recent Developments
9.10 Genomics
9.10.1 Genomics Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.10.2 Genomics Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.10.3 Genomics Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.10.4 Genomics Business Overview
9.10.5 Genomics Recent Developments
10 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET FORECAST BY REGION
10.1 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast
10.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country
10.2.3 Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Region
10.2.4 South America Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Pharmacogenomics Technology (Theranostics and CDx) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Pharmacogenomics Technology (Theranostics and CDx) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Pharmacogenomics Technology (Theranostics and CDx) by Type (2025-2030)
11.1.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Pharmacogenomics Technology (Theranostics and CDx) by Type (2025-2030)
11.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Forecast by Application (2025-2030)
11.2.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) Forecast by Application
11.2.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Pharmacogenomics Technology (Theranostics and CDx)
1.2 Key Market Segments
1.2.1 Pharmacogenomics Technology (Theranostics and CDx) Segment by Type
1.2.2 Pharmacogenomics Technology (Theranostics and CDx) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET COMPETITIVE LANDSCAPE
3.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Manufacturers (2019-2024)
3.2 Global Pharmacogenomics Technology (Theranostics and CDx) Revenue Market Share by Manufacturers (2019-2024)
3.3 Pharmacogenomics Technology (Theranostics and CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Pharmacogenomics Technology (Theranostics and CDx) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Pharmacogenomics Technology (Theranostics and CDx) Sales Sites, Area Served, Product Type
3.6 Pharmacogenomics Technology (Theranostics and CDx) Market Competitive Situation and Trends
3.6.1 Pharmacogenomics Technology (Theranostics and CDx) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Pharmacogenomics Technology (Theranostics and CDx) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) INDUSTRY CHAIN ANALYSIS
4.1 Pharmacogenomics Technology (Theranostics and CDx) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Type (2019-2024)
6.3 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Market Share by Type (2019-2024)
6.4 Global Pharmacogenomics Technology (Theranostics and CDx) Price by Type (2019-2024)
7 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Sales by Application (2019-2024)
7.3 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) by Application (2019-2024)
7.4 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Growth Rate by Application (2019-2024)
8 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET SEGMENTATION BY REGION
8.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.1.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.1.2 Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region
8.2 North America
8.2.1 North America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Pharmacogenomics Technology (Theranostics and CDx) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Illumina
9.1.1 Illumina Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.1.2 Illumina Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.1.3 Illumina Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.1.4 Illumina Business Overview
9.1.5 Illumina Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
9.1.6 Illumina Recent Developments
9.2 Roche
9.2.1 Roche Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.2.2 Roche Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.2.3 Roche Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
9.2.6 Roche Recent Developments
9.3 Agilent
9.3.1 Agilent Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.3.2 Agilent Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.3.3 Agilent Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.3.4 Agilent Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
9.3.5 Agilent Business Overview
9.3.6 Agilent Recent Developments
9.4 Abbott
9.4.1 Abbott Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.4.2 Abbott Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.4.3 Abbott Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.4.4 Abbott Business Overview
9.4.5 Abbott Recent Developments
9.5 Thermofisher
9.5.1 Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.5.2 Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.5.3 Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.5.4 Thermofisher Business Overview
9.5.5 Thermofisher Recent Developments
9.6 Qiagen
9.6.1 Qiagen Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.6.2 Qiagen Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.6.3 Qiagen Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.6.4 Qiagen Business Overview
9.6.5 Qiagen Recent Developments
9.7 Guardant Health
9.7.1 Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.7.2 Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.7.3 Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.7.4 Guardant Health Business Overview
9.7.5 Guardant Health Recent Developments
9.8 MGI Tech Co., Ltd.
9.8.1 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.8.2 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.8.4 MGI Tech Co., Ltd. Business Overview
9.8.5 MGI Tech Co., Ltd. Recent Developments
9.9 Amoydx Biology
9.9.1 Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.9.2 Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.9.4 Amoydx Biology Business Overview
9.9.5 Amoydx Biology Recent Developments
9.10 Genomics
9.10.1 Genomics Pharmacogenomics Technology (Theranostics and CDx) Basic Information
9.10.2 Genomics Pharmacogenomics Technology (Theranostics and CDx) Product Overview
9.10.3 Genomics Pharmacogenomics Technology (Theranostics and CDx) Product Market Performance
9.10.4 Genomics Business Overview
9.10.5 Genomics Recent Developments
10 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS AND CDX) MARKET FORECAST BY REGION
10.1 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast
10.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country
10.2.3 Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Region
10.2.4 South America Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Pharmacogenomics Technology (Theranostics and CDx) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Pharmacogenomics Technology (Theranostics and CDx) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Pharmacogenomics Technology (Theranostics and CDx) by Type (2025-2030)
11.1.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Pharmacogenomics Technology (Theranostics and CDx) by Type (2025-2030)
11.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Forecast by Application (2025-2030)
11.2.1 Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) Forecast by Application
11.2.2 Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Pharmacogenomics Technology (Theranostics and CDx) Market Size Comparison by Region (M USD)
Table 5. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Pharmacogenomics Technology (Theranostics and CDx) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Pharmacogenomics Technology (Theranostics and CDx) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology (Theranostics and CDx) as of 2022)
Table 10. Global Market Pharmacogenomics Technology (Theranostics and CDx) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Pharmacogenomics Technology (Theranostics and CDx) Sales Sites and Area Served
Table 12. Manufacturers Pharmacogenomics Technology (Theranostics and CDx) Product Type
Table 13. Global Pharmacogenomics Technology (Theranostics and CDx) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Pharmacogenomics Technology (Theranostics and CDx)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pharmacogenomics Technology (Theranostics and CDx) Market Challenges
Table 22. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Type (K Units)
Table 23. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size by Type (M USD)
Table 24. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) by Type (2019-2024)
Table 25. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Type (2019-2024)
Table 26. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) by Type (2019-2024)
Table 27. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Share by Type (2019-2024)
Table 28. Global Pharmacogenomics Technology (Theranostics and CDx) Price (USD/Unit) by Type (2019-2024)
Table 29. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) by Application
Table 30. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size by Application
Table 31. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Application (2019-2024) & (K Units)
Table 32. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Application (2019-2024)
Table 33. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Application (2019-2024) & (M USD)
Table 34. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application (2019-2024)
Table 35. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Growth Rate by Application (2019-2024)
Table 36. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Region (2019-2024) & (K Units)
Table 37. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region (2019-2024)
Table 38. North America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country (2019-2024) & (K Units)
Table 39. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales by Region (2019-2024) & (K Units)
Table 41. South America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales by Region (2019-2024) & (K Units)
Table 43. Illumina Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 44. Illumina Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 45. Illumina Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Illumina Business Overview
Table 47. Illumina Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
Table 48. Illumina Recent Developments
Table 49. Roche Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 50. Roche Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 51. Roche Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Roche Business Overview
Table 53. Roche Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
Table 54. Roche Recent Developments
Table 55. Agilent Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 56. Agilent Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 57. Agilent Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Agilent Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
Table 59. Agilent Business Overview
Table 60. Agilent Recent Developments
Table 61. Abbott Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 62. Abbott Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 63. Abbott Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Abbott Business Overview
Table 65. Abbott Recent Developments
Table 66. Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 67. Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 68. Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Thermofisher Business Overview
Table 70. Thermofisher Recent Developments
Table 71. Qiagen Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 72. Qiagen Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 73. Qiagen Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Qiagen Business Overview
Table 75. Qiagen Recent Developments
Table 76. Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 77. Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 78. Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Guardant Health Business Overview
Table 80. Guardant Health Recent Developments
Table 81. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 82. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 83. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. MGI Tech Co., Ltd. Business Overview
Table 85. MGI Tech Co., Ltd. Recent Developments
Table 86. Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 87. Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 88. Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Amoydx Biology Business Overview
Table 90. Amoydx Biology Recent Developments
Table 91. Genomics Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 92. Genomics Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 93. Genomics Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Genomics Business Overview
Table 95. Genomics Recent Developments
Table 96. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Pharmacogenomics Technology (Theranostics and CDx) Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Pharmacogenomics Technology (Theranostics and CDx) Market Size Comparison by Region (M USD)
Table 5. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Pharmacogenomics Technology (Theranostics and CDx) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Pharmacogenomics Technology (Theranostics and CDx) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology (Theranostics and CDx) as of 2022)
Table 10. Global Market Pharmacogenomics Technology (Theranostics and CDx) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Pharmacogenomics Technology (Theranostics and CDx) Sales Sites and Area Served
Table 12. Manufacturers Pharmacogenomics Technology (Theranostics and CDx) Product Type
Table 13. Global Pharmacogenomics Technology (Theranostics and CDx) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Pharmacogenomics Technology (Theranostics and CDx)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pharmacogenomics Technology (Theranostics and CDx) Market Challenges
Table 22. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Type (K Units)
Table 23. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size by Type (M USD)
Table 24. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) by Type (2019-2024)
Table 25. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Type (2019-2024)
Table 26. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) by Type (2019-2024)
Table 27. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Share by Type (2019-2024)
Table 28. Global Pharmacogenomics Technology (Theranostics and CDx) Price (USD/Unit) by Type (2019-2024)
Table 29. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) by Application
Table 30. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size by Application
Table 31. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Application (2019-2024) & (K Units)
Table 32. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Application (2019-2024)
Table 33. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Application (2019-2024) & (M USD)
Table 34. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application (2019-2024)
Table 35. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Growth Rate by Application (2019-2024)
Table 36. Global Pharmacogenomics Technology (Theranostics and CDx) Sales by Region (2019-2024) & (K Units)
Table 37. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region (2019-2024)
Table 38. North America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country (2019-2024) & (K Units)
Table 39. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales by Region (2019-2024) & (K Units)
Table 41. South America Pharmacogenomics Technology (Theranostics and CDx) Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales by Region (2019-2024) & (K Units)
Table 43. Illumina Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 44. Illumina Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 45. Illumina Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Illumina Business Overview
Table 47. Illumina Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
Table 48. Illumina Recent Developments
Table 49. Roche Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 50. Roche Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 51. Roche Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Roche Business Overview
Table 53. Roche Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
Table 54. Roche Recent Developments
Table 55. Agilent Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 56. Agilent Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 57. Agilent Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Agilent Pharmacogenomics Technology (Theranostics and CDx) SWOT Analysis
Table 59. Agilent Business Overview
Table 60. Agilent Recent Developments
Table 61. Abbott Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 62. Abbott Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 63. Abbott Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Abbott Business Overview
Table 65. Abbott Recent Developments
Table 66. Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 67. Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 68. Thermofisher Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Thermofisher Business Overview
Table 70. Thermofisher Recent Developments
Table 71. Qiagen Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 72. Qiagen Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 73. Qiagen Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Qiagen Business Overview
Table 75. Qiagen Recent Developments
Table 76. Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 77. Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 78. Guardant Health Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Guardant Health Business Overview
Table 80. Guardant Health Recent Developments
Table 81. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 82. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 83. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. MGI Tech Co., Ltd. Business Overview
Table 85. MGI Tech Co., Ltd. Recent Developments
Table 86. Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 87. Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 88. Amoydx Biology Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Amoydx Biology Business Overview
Table 90. Amoydx Biology Recent Developments
Table 91. Genomics Pharmacogenomics Technology (Theranostics and CDx) Basic Information
Table 92. Genomics Pharmacogenomics Technology (Theranostics and CDx) Product Overview
Table 93. Genomics Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Genomics Business Overview
Table 95. Genomics Recent Developments
Table 96. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Pharmacogenomics Technology (Theranostics and CDx) Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Pharmacogenomics Technology (Theranostics and CDx)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD), 2019-2030
Figure 5. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) (2019-2030)
Figure 6. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pharmacogenomics Technology (Theranostics and CDx) Market Size by Country (M USD)
Figure 11. Pharmacogenomics Technology (Theranostics and CDx) Sales Share by Manufacturers in 2023
Figure 12. Global Pharmacogenomics Technology (Theranostics and CDx) Revenue Share by Manufacturers in 2023
Figure 13. Pharmacogenomics Technology (Theranostics and CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Pharmacogenomics Technology (Theranostics and CDx) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Pharmacogenomics Technology (Theranostics and CDx) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Type
Figure 18. Sales Market Share of Pharmacogenomics Technology (Theranostics and CDx) by Type (2019-2024)
Figure 19. Sales Market Share of Pharmacogenomics Technology (Theranostics and CDx) by Type in 2023
Figure 20. Market Size Share of Pharmacogenomics Technology (Theranostics and CDx) by Type (2019-2024)
Figure 21. Market Size Market Share of Pharmacogenomics Technology (Theranostics and CDx) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application
Figure 24. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Application (2019-2024)
Figure 25. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Application in 2023
Figure 26. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application (2019-2024)
Figure 27. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application in 2023
Figure 28. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region (2019-2024)
Figure 30. North America Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Country in 2023
Figure 32. U.S. Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Pharmacogenomics Technology (Theranostics and CDx) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Country in 2023
Figure 37. Germany Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region in 2023
Figure 44. China Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (K Units)
Figure 50. South America Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Country in 2023
Figure 51. Brazil Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share Forecast by Type (2025-2030)
Figure 65. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Application (2025-2030)
Figure 66. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Pharmacogenomics Technology (Theranostics and CDx)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD), 2019-2030
Figure 5. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size (M USD) (2019-2030)
Figure 6. Global Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pharmacogenomics Technology (Theranostics and CDx) Market Size by Country (M USD)
Figure 11. Pharmacogenomics Technology (Theranostics and CDx) Sales Share by Manufacturers in 2023
Figure 12. Global Pharmacogenomics Technology (Theranostics and CDx) Revenue Share by Manufacturers in 2023
Figure 13. Pharmacogenomics Technology (Theranostics and CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Pharmacogenomics Technology (Theranostics and CDx) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Pharmacogenomics Technology (Theranostics and CDx) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Type
Figure 18. Sales Market Share of Pharmacogenomics Technology (Theranostics and CDx) by Type (2019-2024)
Figure 19. Sales Market Share of Pharmacogenomics Technology (Theranostics and CDx) by Type in 2023
Figure 20. Market Size Share of Pharmacogenomics Technology (Theranostics and CDx) by Type (2019-2024)
Figure 21. Market Size Market Share of Pharmacogenomics Technology (Theranostics and CDx) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application
Figure 24. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Application (2019-2024)
Figure 25. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Application in 2023
Figure 26. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application (2019-2024)
Figure 27. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share by Application in 2023
Figure 28. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region (2019-2024)
Figure 30. North America Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Country in 2023
Figure 32. U.S. Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Pharmacogenomics Technology (Theranostics and CDx) Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Pharmacogenomics Technology (Theranostics and CDx) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Country in 2023
Figure 37. Germany Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region in 2023
Figure 44. China Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (K Units)
Figure 50. South America Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Country in 2023
Figure 51. Brazil Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Pharmacogenomics Technology (Theranostics and CDx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Pharmacogenomics Technology (Theranostics and CDx) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share Forecast by Type (2025-2030)
Figure 65. Global Pharmacogenomics Technology (Theranostics and CDx) Sales Forecast by Application (2025-2030)
Figure 66. Global Pharmacogenomics Technology (Theranostics and CDx) Market Share Forecast by Application (2025-2030)
